Analysts expect Evolent Health Inc (NYSE:EVH) to report ($0.05) earnings per share (EPS) for the current quarter, according to Zacks. Seven analysts have issued estimates for Evolent Health’s earnings, with the highest EPS estimate coming in at $0.01 and the lowest estimate coming in at ($0.12). Evolent Health reported earnings per share of ($0.07) in the same quarter last year, which indicates a positive year over year growth rate of 28.6%. The company is scheduled to announce its next quarterly earnings results on Tuesday, February 25th.
On average, analysts expect that Evolent Health will report full-year earnings of ($0.70) per share for the current fiscal year, with EPS estimates ranging from ($0.77) to ($0.65). For the next fiscal year, analysts expect that the business will report earnings of ($0.21) per share, with EPS estimates ranging from ($0.56) to $0.37. Zacks Investment Research’s EPS calculations are a mean average based on a survey of sell-side research analysts that follow Evolent Health.
Evolent Health (NYSE:EVH) last posted its earnings results on Tuesday, November 5th. The technology company reported ($0.09) EPS for the quarter, topping the consensus estimate of ($0.12) by $0.03. The company had revenue of $220.14 million during the quarter, compared to the consensus estimate of $217.90 million. Evolent Health had a negative net margin of 15.02% and a negative return on equity of 6.93%. The firm’s revenue for the quarter was up 46.8% on a year-over-year basis. During the same period in the previous year, the firm posted ($0.04) earnings per share.
Several equities research analysts have recently commented on EVH shares. Piper Jaffray Companies reissued a “buy” rating and set a $10.15 target price on shares of Evolent Health in a research report on Wednesday, December 18th. SunTrust Banks reissued a “buy” rating and set a $14.00 target price on shares of Evolent Health in a research report on Wednesday, December 4th. KeyCorp decreased their target price on shares of Evolent Health from $20.00 to $10.00 and set an “overweight” rating for the company in a research report on Monday, December 2nd. They noted that the move was a valuation call. ValuEngine raised shares of Evolent Health from a “hold” rating to a “buy” rating in a research report on Friday, January 3rd. Finally, Wells Fargo & Co reduced their price objective on shares of Evolent Health from $19.00 to $17.00 and set an “overweight” rating for the company in a research report on Wednesday, January 8th. One research analyst has rated the stock with a sell rating and eight have given a buy rating to the company. The company has an average rating of “Buy” and an average price target of $13.49.
In related news, President Seth Blackley bought 14,749 shares of Evolent Health stock in a transaction dated Wednesday, December 4th. The stock was purchased at an average cost of $6.68 per share, with a total value of $98,523.32. 4.50% of the stock is owned by corporate insiders.
Several institutional investors have recently added to or reduced their stakes in the company. Conestoga Capital Advisors LLC grew its position in shares of Evolent Health by 107.3% during the 4th quarter. Conestoga Capital Advisors LLC now owns 62,990 shares of the technology company’s stock valued at $570,000 after acquiring an additional 32,600 shares during the period. Metropolitan Life Insurance Co NY grew its position in shares of Evolent Health by 7.3% during the 3rd quarter. Metropolitan Life Insurance Co NY now owns 22,380 shares of the technology company’s stock valued at $161,000 after acquiring an additional 1,521 shares during the period. Squarepoint Ops LLC bought a new position in shares of Evolent Health during the 3rd quarter valued at approximately $1,568,000. Voloridge Investment Management LLC grew its position in shares of Evolent Health by 12.4% during the 3rd quarter. Voloridge Investment Management LLC now owns 137,247 shares of the technology company’s stock valued at $987,000 after acquiring an additional 15,190 shares during the period. Finally, Granahan Investment Management Inc. MA grew its position in shares of Evolent Health by 7.9% during the 3rd quarter. Granahan Investment Management Inc. MA now owns 306,525 shares of the technology company’s stock valued at $2,204,000 after acquiring an additional 22,347 shares during the period. 98.74% of the stock is owned by hedge funds and other institutional investors.
Shares of NYSE:EVH traded down $0.34 during midday trading on Friday, hitting $10.94. 1,265,602 shares of the company’s stock were exchanged, compared to its average volume of 1,333,747. The company has a debt-to-equity ratio of 0.27, a current ratio of 1.19 and a quick ratio of 1.19. The stock has a 50 day moving average price of $9.13 and a 200-day moving average price of $7.95. The company has a market cap of $954.39 million, a PE ratio of -7.39 and a beta of 1.11. Evolent Health has a 12 month low of $5.50 and a 12 month high of $18.20.
Evolent Health Company Profile
Evolent Health, Inc, through its subsidiary, Evolent Health LLC, provides health care delivery and payment solutions in the United States. The company operates as a managed services firm that supports health systems and physician organizations in migration toward value-based care and population health management.
Featured Story: How prevalent are 12b-1 fees?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Evolent Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evolent Health and related companies with MarketBeat.com's FREE daily email newsletter.